Literature DB >> 2234715

Aggressive or expectant management for patients with severe preeclampsia between 28-34 weeks' gestation: a randomized controlled trial.

H J Odendaal1, R C Pattinson, R Bam, D Grove, T J Kotze.   

Abstract

Fifty-eight women with severe preeclampsia between 28-34 weeks' gestation qualified for a randomized controlled trial to establish whether elective delivery 48 hours after administration of betamethasone (aggressive-management group) or delivery later as indicated by maternal or fetal condition (expectant-management group) was more beneficial to maternal and fetal outcome. Twenty women who qualified were not randomized because they developed maternal or fetal indications necessitating delivery within 48 hours; these newborns developed most of the complications. Expectant management was not associated with an increase in maternal complications, but it significantly prolonged the gestational age (mean 7.1 days; P less than .05), reduced the number of neonates requiring ventilation (P less than .05), and reduced the number of neonatal complications (P less than .05).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2234715

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  27 in total

Review 1.  Fortnightly review: management of hypertension in pregnancy.

Authors:  L A Magee; M P Ornstein; P von Dadelszen
Journal:  BMJ       Date:  1999-05-15

2.  Expectant or outpatient management of preeclampsia before 34 weeks: safe for mother but associated with increased stillbirth risk.

Authors:  Jing Fu; Chunfang Li; Wenli Gou; Arier Lee; Xuelan Li; Qi Chen
Journal:  J Hum Hypertens       Date:  2019-02-11       Impact factor: 3.012

3.  An analysis of expectant management in women with early-onset preeclampsia in China.

Authors:  Q Chen; F Shen; Y F Gao; M Zhao
Journal:  J Hum Hypertens       Date:  2014-10-23       Impact factor: 3.012

4.  Report of the Canadian Hypertension Society Consensus Conference: 1. Definitions, evaluation and classification of hypertensive disorders in pregnancy.

Authors:  M E Helewa; R F Burrows; J Smith; K Williams; P Brain; S W Rabkin
Journal:  CMAJ       Date:  1997-09-15       Impact factor: 8.262

5.  Formal measurement of clinical uncertainty: prelude to a trial in perinatal medicine. The Fetal Compromise Group.

Authors:  R Lilford
Journal:  BMJ       Date:  1994-01-08

6.  Maternal and perinatal outcome during expectant management of severe pre-eclampsia between 24 and 34 weeks of gestation.

Authors:  M K Swamy; Kamal Patil; Shailaja Nageshu
Journal:  J Obstet Gynaecol India       Date:  2012-10-23

7.  Diagnosis and Treatment of Hypertensive Pregnancy Disorders. Guideline of DGGG (S1-Level, AWMF Registry No. 015/018, December 2013).

Authors:  H Stepan; S Kuse-Föhl; W Klockenbusch; W Rath; B Schauf; T Walther; D Schlembach
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-09       Impact factor: 2.915

8.  Induction, labor length and mode of delivery: the impact on preeclampsia-related adverse maternal outcomes.

Authors:  L D Levine; M A Elovitz; M Limaye; M D Sammel; S K Srinivas
Journal:  J Perinatol       Date:  2016-05-19       Impact factor: 2.521

9.  Does aggressive and expectant management of severe preeclampsia affect the neurologic development of the infant?

Authors:  Arif Aktuğ Ertekin; Bilge Kapudere; Meryem Kurek Eken; Gülşah İlhan; Şükriye Dırman; Mehmet Akif Sargın; Engin Deniz; Güner Karatekin; Ebru Çöğendez; Murat Api
Journal:  Int J Clin Exp Med       Date:  2015-10-15

10.  Adverse maternal and neonatal outcomes among women with preeclampsia with severe features <34 weeks gestation with versus without comorbidity.

Authors:  Kartik K Venkatesh; Robert A Strauss; Daniel J Westreich; John M Thorp; David M Stamilio; Katherine L Grantz
Journal:  Pregnancy Hypertens       Date:  2020-03-10       Impact factor: 2.899

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.